Vivos Therapeutics Reports 6% Revenue Decline and $5M Net Loss in Q2 2025

Vivos Therapeutics, Inc. reported a total revenue of $3.8 million for the three months ended June 30, 2025, a decrease of approximately 6% compared to $4.1 million for the same period in 2024. The decline was attributed to a drop in both product and service revenues, with product revenue falling to $1.9 million from $2.0 million and service revenue decreasing to $1.9 million from $2.1 million. For the six months ended June 30, 2025, total revenue was $6.8 million, down 9% from $7.5 million in the prior year. The company reported a net loss of $5.0 million for the second quarter and $8.9 million for the first half of 2025, compared to losses of $1.9 million and $5.7 million, respectively, in the same periods of 2024.

The company experienced significant changes in its financial performance, particularly in operating expenses, which rose to $7.0 million in the second quarter of 2025, up from $4.6 million in the same quarter of 2024. This increase was primarily driven by costs associated with the acquisition and integration of The Sleep Center of Nevada (SCN), which Vivos acquired on June 10, 2025, for a total consideration of $8.7 million. The acquisition included $6.0 million in cash, 607,287 shares of common stock valued at $1.3 million, and contingent earn-out consideration of $1.4 million. The integration of SCN is expected to enhance Vivos's operational capabilities and revenue generation potential.

Operationally, Vivos reported a total of 7,324,807 shares outstanding as of June 30, 2025, reflecting an increase from 5,889,520 shares at the end of 2024. The company has also expanded its employee base, with 111 employees as of the latest reporting period. The acquisition of SCN is anticipated to provide a new revenue stream through its sleep testing and treatment services, which Vivos plans to integrate with its existing product offerings. The company aims to leverage SCN's established patient base to drive sales of its proprietary oral appliances.

Looking ahead, Vivos has expressed a cautious outlook, emphasizing the need for additional financing to support its operations and strategic objectives. As of June 30, 2025, the company had approximately $4.4 million in cash and cash equivalents, which it indicated would not be sufficient to fund operations over the next twelve months without further capital raises. The company is actively exploring additional acquisition opportunities and strategic alliances to enhance its market position and revenue growth. However, it acknowledged the risks associated with its new business model and the ongoing integration of SCN, which may impact its financial performance in the near term.